Cisplatin and quantum dots encapsulated in liposomes as multifunctional nanocarriers for theranostic use in brain and skin
Source abstract
Abstract
We aimed to develop liposomes for loading both cisplatin and quantum dots (QDs) for both drug delivery and bioimaging. The resultant quantum-dot-liposomes (QDLs) with cisplatin were characterized using dynamic light scattering, transmission electron microscopy (TEM), encapsulation efficiencies, and fluorescence intensity. QDLs composed of CdSe or CdSe/ZnS QDs represented a size of about 100 nm. The QDLs were prepared at a high QD loading efficiency of nearly 100 %. Most QDs were located within the liposomal bilayers as evidenced by TEM. Slow and sustained cisplatin release from QDLs was achieved. The cellular uptake of QDLs demonstrated effective internalization and significant fluorescence in melanoma cells. The signal derived from QDLs could be observed by different wavelength settings. The cisplatin-containing QDLs revealed higher cytotoxic activity compared to an equal dose of free cisplatin. CdSe/ZnS QDLs were intravenously administered to mice, and the biodistribution was observed with an in vivo imaging system. Significant fluorescence signal and cisplatin accumulation were detected in the brain and skin, as verified by ex vivo imaging and drug distribution. Liposomal inclusion could reduce the reticuloendothelial system uptake of QDs and cisplatin. QDLs evaluated in this study represent a new potential method for theranostic purposes.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Quantum Dots Synthesis And Properties · Carbon and Quantum Dots Applications · Chalcogenide Semiconductor Thin Films
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (59)
Show source-provided references
1. Algar WR, Massey M, Krull UJ (2009) The application of quantum dots, gold nanoparticles and molecular switches to optical nucleic-acid diagnostics. Trends Anal Chem 28:292–30610.1016/j.trac.2008.11.012 ↗
2. Al-Jamal WT, Al-Jamal KT, Bomans PH, Frederik PM, Kostarelos K (2008) Functionalized-quantum-dot-liposome hybrids as multimodal nanoparticles for cancer. Small 4:1406–141510.1002/smll.200701043 ↗
3. Alvarez-Román R, Naik A, Kalia YN, Guy RH, Fessi H (2004) Skin penetration and distribution of polymeric nanoparticles. J Controlled Release 99:53–6210.1016/j.jconrel.2004.06.015 ↗
4. Arashiro K (2002) The tumor vasculature in cutaneous malignant melanoma: scanning electron microscopy of corrosion casts. Plast Reconstr Surg 110:717–71810.1097/00006534-200208000-00075 ↗
5. Biju V, Mundayoor S, Omkumar RV, Anas A, Ishikawa M (2010) Bioconjugated quantum dots for cancer research: present status, prospects and remaining issues. Biotechnol Adv 28:199–21310.1016/j.biotechadv.2009.11.007 ↗
6. Bothun GD, Rabideau AE, Stoner MA (2009) Hepatoma cell uptake of cationic multifluorescent quantum dot liposomes. J Phys Chem B 113:7725–772810.1021/jp9017458 ↗
7. Bowden NA, Ashton KA, Avery-Kiejda KA, Zhang XD, Hersey P, Scott RJ (2010) Nucleotide excision repair gene expression after cisplatin treatment in melanoma. Cancer Res 70:7918–792610.1158/0008-5472.CAN-10-0161 ↗
8. Brown MD, Schätzlein AG, Uchegbu IF (2001) Gene delivery with synthetic (non viral) carriers. Int J Pharm 229:1–2110.1016/S0378-5173(01)00861-4 ↗
9. Cheng FY, Wang SPH, Su CH, Tsai TL, Wu PC, Shieh DB, Chen JH, Hsieh PCH, Yeh CS (2008) Stabilizer-free poly(lactide-co-glycolide) nanoparticles for multimodal biomedical probes. Biomaterials 29:2104–211210.1016/j.biomaterials.2008.01.010 ↗
10. Chung H, Kim TW, Kwon M, Kwon IC, Jeong SY (2001) Oil components modulate physical characteristics and function of the natural oil emulsions as drug or gene delivery system. J Controlled Release 71:339–35010.1016/S0168-3659(00)00363-1 ↗
11. Clarke SJ, Hollmann CA, Zhang Z, Suffern D, Bradforth SE, Dimitrijevic NM, Minarik WG, Nadeau JL (2006) Photophysics of dopamine-modified quantum dots and effects on biological systems. Nat Mater 5:409–41710.1038/nmat1631 ↗
12. Cornish D, Holterhues C, van de Poll-Franse LV, Coebergh JW, Nijsten T (2009) A systematic review of health-related quality of life in cutaneous melanoma. Ann Oncol 20(Suppl 6):51–5810.1093/annonc/mdp255 ↗
13. Dudu V, Ramcharan M, Gilchrist ML, Holland EC, Vazquez M (2008) Liposome delivery of quantum dots to the cytosol of live cells. J Nanosci Nanotechnol 8:2293–230010.1166/jnn.2008.185 ↗
14. Fang JY, Hung CF, Hwang TL, Huang YL (2005) Physicochemical characteristics and in vivo deposition of liposome-encapsulated tea catechins by topical and intratumor administrations. J Drug Target 13:19–2710.1080/10611860400015977 ↗
15. Fang JY, Hwang TL, Huang YL (2006) Liposomes as vehicles for enhancing drug delivery via skin routes. Curr Nanosci 2:55–7010.2174/157341306775473791 ↗
16. Guo G, Lin W, Liang J, He Z, Xu H, Yang X (2007) Probing the cytotoxicity of CdSe quantum dots with surface modification. Mater Lett 61:1641–164410.1016/j.matlet.2006.07.105 ↗
17. Harrington KJ, Syrigos KN, Vile RG (2002) Liposomally targeted cytotoxic drugs for the treatment of cancer. J Pharm Pharmacol 54:1573–160010.1211/0022357002243 ↗
18. Hidalgo E, Domínguez C (1998) Study of cytotoxicity mechanisms of silver nitrate in human dermal fibroblasts. Toxicol Lett 98:169–17910.1016/S0378-4274(98)00114-3 ↗
19. Hsu SH, Al-Suwayeh SA, Chen CC, Chi CH, Fang JY (2011) PEGylated liposomes incorporated with nonionic surfactants as an apomorphine delivery system targeting the brain: in vitro release and in vivo real-time imaging. Curr Nanosci 7:191–19910.2174/157341311794653686 ↗
20. Huang ZR, Hua SC, Yang YL, Fang JY (2008) Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol Sin 29:1094–110210.1111/j.1745-7254.2008.00829.x ↗
21. Hwang TL, Lee WR, Hua SC, Fang JY (2007) Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas. J Dermatol Sci 46:11–2010.1016/j.jdermsci.2006.12.011 ↗
22. Hwang TL, Fang CL, Chen CH, Fang JY (2009a) Permeation enhancer-containing water-in-oil nanoemulsions as carriers for intravesical cisplatin delivery. Pharm Res 26:2314–232310.1007/s11095-009-9947-6 ↗
23. Hwang TL, Lin YK, Chi CH, Huang TH, Fang JY (2009b) Development and evaluation of perfluorocarbon nanobubbles for apomorphine delivery. J Pharm Sci 98:3735–374710.1002/jps.21687 ↗
24. Jamieson T, Bakhshi R, Petrova D, Pocock R, Imani M, Seifalian AM (2007) Biological applications of quantum dots. Biomaterials 28:4717–473210.1016/j.biomaterials.2007.07.014 ↗
25. Jeong SH, Kim JH, Yi SM, Lee JP, Kim JH, Sohn KH, Park KL, Kim MK, Son SW (2010) Assessment of penetration of quantum dots through in vitro and in vivo human skin using the human skin equivalent model and the tape stripping method. Biochem Biophys Res Commun 394:612–61510.1016/j.bbrc.2010.03.032 ↗
26. Kloepfer JA, Cohen N, Nadeau JL (2004) FRET between CdSe quantum dots in lipid vesicles and water- and lipid-soluble dyes. J Phys Chem B 108:17042–1704910.1021/jp048094c ↗
27. Koziara JM, Lockman PR, Allen DD, Mumper RJ (2006) The blood–brain barrier and brain drug delivery. J Nanosci Nanotechnol 6:2712–273510.1166/jnn.2006.441 ↗
28. Larson DR, Zipfel WR, Williams RM, Clark SW, Bruchez MP, Wise FW, Webb WW (2003) Water-soluble quantum dots for multiphoton fluorescence imaging in vivo. Science 300:1434–143610.1126/science.1083780 ↗
29. MacKie RM, Hauschild A, Eggermont AMM (2009) Epidemiology of invasive cutaneous melanoma. Ann Oncol 20(Suppl 6):1–710.1093/annonc/mdp252 ↗
30. Martin OC, Pagano RE (1987) Transbilayer movement of fluorescent analogs of phosphatidylserine and phosphatidylethanolamine at the plasma membrane of cultured cells. J Biol Chem 262:5890–589810.1016/S0021-9258(18)45658-X ↗
31. Marty C, Schwendener RA (2005) Cytotoxic tumor targeting with scFv antibody-modified liposomes. Adopt Immunother 109:389–40110.1385/1-59259-862-5:389 ↗
32. Maruyama K, Ishida O, Takizawa T, Moribe K (1999) Possibility of active targeting to tumor tissues with liposomes. Adv Drug Deliv Rev 40:89–10210.1016/S0169-409X(99)00042-3 ↗
33. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H (2005) Quantum dot bioconjugates for imaging, labeling and sensing. Nat Mater 4:435–44610.1038/nmat1390 ↗
34. Müller RH, Jacobs C, Kayser O (2001) Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47:3–1910.1016/S0169-409X(00)00118-6 ↗
35. Ozkan M (2004) Quantum dots and other nanoparticles: what can they offer to drug discovery? Drug Discov Today 9:1065–107110.1016/S1359-6446(04)03291-X ↗
36. Pan J, Feng SS (2009) Targeting and imaging cancer cells by folate-decorated, quantum dots (QDs)-loaded nanoparticles of biodegradable polymers. Biomaterials 30:1176–118310.1016/j.biomaterials.2008.10.039 ↗
37. Parak N, Pellegrino T, Plank C (2005) Labelling of cells with quantum dots. Nanotechnology 16:R9–R1510.1088/0957-4484/16/2/R01 ↗
38. Qin Y, Fan W, Chen H, Yao N, Tang W, Tang J, Yuan W, Kuai R, Zhang Z, Wu Y, He Q (2010) In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J Drug Target 18:536–54910.3109/10611861003587235 ↗
39. Saito H, Miyako Y, Handa T, Miyajima K (1997) Effect of cholesterol on apolipoprotein A-I binding to lipid bilayers and emulsions. J Lipid Res 38:287–29410.1016/S0022-2275(20)37441-1 ↗
40. Schroeder JE, Shweky I, Shmeeda H, Banin U, Gabizon AA (2007) Folate-mediated tumor cell uptake of quantum dots entrapped in lipid nanoparticles. J Controlled Release 124:28–3410.1016/j.jconrel.2007.08.028 ↗
41. Sigot V, Arndt-Jovin DJ, Jovin TM (2010) Targeted cellular delivery of quantum dots loaded on and in biotinylated liposomes. Bioconjugate Chem 21:1465–147210.1021/bc100054c ↗
42. Simberg D, Weisman S, Talmon Y, Barenholz Y (2004) DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst 4:257–31710.1615/CritRevTherDrugCarrierSyst.v21.i4.10 ↗
43. Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, Kulms D, Maczey E, Campos M, Gogel J, Garbe C, Meier F (2009) Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol 129:1500–151510.1038/jid.2008.379 ↗
44. Sleight RG, Pagano RE (1985) Transbilayer movement of a fluorescent phosphatidylethanolamine analogue across the plasma membranes of cultured mammalian cells. J Biol Chem 260:1146–115410.1016/S0021-9258(20)71220-2 ↗
45. Smith AM, Duan H, Rhyner MN, Ruan G, Nie S (2006) A systematic examination of surface coatings on the optical and chemical properties of semiconductor quantum dots. Phys Chem Chem Phys 8:3895–390310.1039/b606572b ↗
46. Susumu K, Mei BC (2009) Multifunctional ligands based on dihydrolipoic acid and polyethylene glycol to promote biocompatibility of quantum dots. Nat Protoc 4:424–43610.1038/nprot.2008.247 ↗
47. Tamaddon AM, Shirazi FH, Moghimi HR (2007) Modeling cytoplasmic release of encapsulated oligonucleotides from cationic liposomes. Int J Pharm 336:174–18210.1016/j.ijpharm.2006.11.048 ↗
48. van Hennik MB, van der Vijgh WJF, Klein I, Elferink F, Vermorken JB, Winograd B, Pinedo HM (1987) Comparative pharmacokinetics of cisplatin and three analogues in mice and humans. Cancer Res 47:6297–6301
49. Wang Y, Chen L (2011) Quantum dots, lighting up the research and development of nanomedicine. Nanomed-Nanotechnol Biol Med 7:385–40210.1016/j.nano.2010.12.006 ↗
50. Wang J, Maitani Y, Takayama K (2002) Antitumor effects and pharmacokinetics of aclacinomycin A carried by injectable emulsions composed of vitamin E, cholesterol, and PEG-lipid. J Pharm Sci 91:1128–113410.1002/jps.10104 ↗
51. Wang C, Gao X, Su X (2010) In vitro and in vivo imaging with quantum dots. Anal Bioanal Chem 397:1397–141510.1007/s00216-010-3481-6 ↗
52. Xue M, Wang X, Wang H, Tang B (2011) The preparation of glutathione-capped CdTe quantum dots and their use in imaging of cells. Talanta 83:1680–168610.1016/j.talanta.2010.11.064 ↗
53. Yang RSH, Chang LW, Wu JP, Tsai MH, Wang HJ, Kuo YC, Yeh TK, Yang CS, Lin P (2007) Persistent tissue kinetics and redistribution of nanoparticles, quantum dot 705, in mice: iCRMS quantitative assessment. Environ Health Perspect 115:1339–134310.1289/ehp.10290 ↗
54. Yokoyama M, Okano T, Sakurai Y, Suwa S, Kataoka K (1996) Introduction of cisplatin into polymeric micelle. J Controlled Release 39:351–35610.1016/0168-3659(95)00165-4 ↗
55. Yong KT (2010) Biophotonics and biotechnology in pancreatic cancer: cyclic RGD-peptide-conjugated type II quantum dots for in vivo imaging. Pancreatology 10:553–56410.1159/000283577 ↗
56. Yotsuyanagi T, Usami M, Noda Y, Nagata M (2002) Computational consideration of cisplatin hydrolysis and acid dissociation in aqueous media: effect of total drug concentrations. Int J Pharm 246:95–10410.1016/S0378-5173(02)00382-4 ↗
57. Zhang LW, Monteiro-Riviere NA (2008) Assessment of quantum dot penetration into intact, tape-stripped, abraded and flexed rat skin. Skin Pharmacol Physiol 21:166–18010.1159/000131080 ↗
58. Zhang X, Xie J, Li S, Wang X, Hou X (2003) The study on brain targeting of the amphotericin B liposomes. J Drug Target 11:117–12210.1080/1061186031000115150 ↗
59. Zhang H, Zeng X, Li Q, Gaillard-Kelly M, Wagner CR, Yee D (2009) Fluorescent tumor imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore. Br J Cancer 101:71–7910.1038/sj.bjc.6605103 ↗